'Pfizer And BioNTech Initiate Application To European Medicines Agency For Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine'
Portfolio Pulse from Benzinga Newsdesk
Pfizer and BioNTech have initiated an application to the European Medicines Agency (EMA) for their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine for the 2023-2024 fall and winter season. The companies expect to ship the adapted vaccines to EU member states immediately following regulatory approval, with a US application expected in the coming days.
June 23, 2023 | 3:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioNTech has initiated an application to the EMA for its Omicron XBB.1.5-adapted monovalent COVID-19 vaccine, with shipments to EU member states expected after approval and a US application in the coming days.
The news of BioNTech initiating the application to the EMA for its Omicron XBB.1.5-adapted COVID-19 vaccine is positive for the company, as it shows progress in addressing the evolving pandemic. If approved, this could lead to increased sales and revenue for BioNTech, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Pfizer has initiated an application to the EMA for its Omicron XBB.1.5-adapted COVID-19 vaccine, with shipments to EU member states expected after approval and a US application in the coming days.
The news of Pfizer initiating the application to the EMA for its Omicron XBB.1.5-adapted COVID-19 vaccine is positive for the company, as it shows progress in addressing the evolving pandemic. If approved, this could lead to increased sales and revenue for Pfizer, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100